Vanda Pharmaceuticals, Inc. (VNDA)
3.75
+0.16
(+4.46%)
USD |
NASDAQ |
Nov 06, 10:36
Vanda Pharmaceuticals Enterprise Value : 98.56M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 98.56M |
| November 04, 2026 | 116.10M |
| November 03, 2026 | 108.24M |
| November 02, 2026 | 116.10M |
| October 30, 2026 | 110.66M |
| October 29, 2026 | 126.38M |
| October 28, 2026 | 123.35M |
| October 27, 2026 | 122.75M |
| October 26, 2026 | 119.73M |
| October 23, 2026 | 123.96M |
| October 22, 2026 | 126.38M |
| October 21, 2026 | 123.96M |
| October 20, 2026 | 133.63M |
| October 19, 2026 | 128.80M |
| October 16, 2026 | 125.17M |
| October 15, 2026 | 137.87M |
| October 14, 2026 | 136.66M |
| October 13, 2026 | 141.49M |
| October 12, 2026 | 156.01M |
| October 09, 2026 | 157.82M |
| October 08, 2026 | 155.40M |
| October 07, 2026 | 157.22M |
| October 06, 2026 | 154.80M |
| October 05, 2026 | 158.43M |
| October 02, 2026 | 161.45M |
| Date | Value |
|---|---|
| October 01, 2026 | 172.33M |
| September 30, 2026 | 178.38M |
| September 29, 2026 | 156.79M |
| September 28, 2026 | 165.25M |
| September 25, 2026 | 158.00M |
| September 24, 2026 | 153.76M |
| September 23, 2026 | 157.39M |
| September 22, 2026 | 167.67M |
| September 21, 2026 | 164.34M |
| September 18, 2026 | 162.83M |
| September 17, 2026 | 161.62M |
| September 16, 2026 | 154.97M |
| September 15, 2026 | 154.37M |
| September 14, 2026 | 164.04M |
| September 11, 2026 | 160.41M |
| September 10, 2026 | 157.39M |
| September 09, 2026 | 170.09M |
| September 08, 2026 | 174.92M |
| September 04, 2026 | 180.97M |
| September 03, 2026 | 175.53M |
| September 02, 2026 | 187.01M |
| September 01, 2026 | 180.36M |
| August 31, 2026 | 179.16M |
| August 28, 2026 | 172.51M |
| August 27, 2026 | 181.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SELLAS Life Sciences Group, Inc. | 1.453B |
| Protagonist Therapeutics, Inc. | 7.974B |
| Sagimet Biosciences, Inc. | 325.27M |
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.56M |
| Revenue (Quarterly) | 69.82M |
| Total Expenses (Quarterly) | 92.38M |
| EPS Diluted (Quarterly) | -0.3731 |
| Gross Profit Margin (Quarterly) | 91.21% |
| Profit Margin (Quarterly) | -32.32% |
| Earnings Yield | -123.1% |
| Normalized Earnings Yield | -123.12 |